Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2025-12-11 00:00:00 ET · period of report 2025-12-09 · accession 0001218629-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-11 | 2025-12-09 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | M - OptEx | $555.67 | +172.7K | 369.7K | +88% | +$95.98M |
| D | 2025-12-11 | 2025-12-09 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | F - Tax | $701.51 | -155.1K | 214.5K | -42% | -$108.84M |
| D | 2025-12-11 | 2025-12-09 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | M - OptEx | $0.00 | -172.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-09 | M | A | 172,723 | $555.67 | 369,668 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-09 | F | D | 155,145 | $701.51 | 214,523 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-12-09 | M | D | 172,723 | $0.00 | 0 | D | $555.67 · — to 2025-12-16 | 172,723 Common Stock | (F1) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |